ERN1 and lupus erythematosus: Pharmacological targeting of IRE1α could be explored as a strategy to mitigate endothelial dysfunction and its complications in diseases characterized by systemic or localized fever, such as sepsis, Kawasaki disease, or even certain autoimmune conditions (e.g., lupus erythematosus).